Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) shares dropped 3.1% during mid-day trading on Monday . The company traded as low as $3.61 and last traded at $3.69, with a volume of 578,609 shares changing hands. The stock had previously closed at $3.81.

ANTH has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 19th. Jefferies Group reissued a “buy” rating on shares of Anthera Pharmaceuticals in a report on Thursday, June 9th. FBR & Co reissued a “hold” rating on shares of Anthera Pharmaceuticals in a report on Monday, June 20th. Finally, HC Wainwright initiated coverage on shares of Anthera Pharmaceuticals in a report on Friday, July 8th. They issued a “buy” rating and a $10.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Anthera Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $9.58.

The company has a 50 day moving average price of $3.39 and a 200-day moving average price of $3.50. The firm’s market capitalization is $145.91 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.01. On average, equities research analysts forecast that Anthera Pharmaceuticals Inc. will post ($1.25) earnings per share for the current fiscal year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.